Soligenix Inc (SNGX)

$0.39 0.00 (N/A)
Market Cap 5.78M
Revenue (ttm) 0.00
Net Income (ttm) -11.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 946,100
Avg Vol 991,544
Day's Range N/A - N/A
Shares Out 14.82M
Stochastic %K 84%
Beta 1.31
Analysts Strong Buy
Price Target $1.75

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
YoloAlfred
YoloAlfred May. 22 at 6:26 PM
$SNGX Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses - Sep 4, 2025 https://share.google/a0HcGxqysZk6Rm9a2
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 6:08 PM
$SNGX Next PR...soon.....beginning of HUMAN TRIALS....and i believe it will be fully funded through BARDA( US GOVERNMENT AGENCY) Biomedical Advanced Research and Development Authority.....You will pay $2-$4 a share after that PR
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 5:53 PM
$SNGX Im betting on it....We should have a nice LONG WEEKEND OF EBOLA DREAD sprinkled into each news cycle...this company has been working with BARDA and government. I like that Super pumpers haven't fully arrived yet...after PR ALLwill show up...im cool with it staying in the .36-.41 band
0 · Reply
rrch
rrch May. 22 at 5:46 PM
$SNGX I think an announcement is coming. They have been working on an ebola vaccine for a long time
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 3:43 PM
$SNGX added more
0 · Reply
AlertsAndNews
AlertsAndNews May. 22 at 2:26 PM
$SPY $GOVX $SIGA $LAKE $SNGX oh boy from CBS The head of the World Health Organization said Friday that the Ebola outbreak centered in the Democratic Republic of Congo is "spreading rapidly" and now poses a "very high" risk at the national level. WHO Director-General Tedros Adhanom Ghebreyesus said the United Nations health agency had raised its alert over the risks of the outbreak spreading within Congo, but that it remained lower outside the county.
1 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:49 PM
$SNGX .80-$2.20 very possible
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:47 PM
$SNGX Government support
0 · Reply
Evissamwohs
Evissamwohs May. 22 at 12:44 PM
$SNGX More shenanigans Pre Market.
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:40 PM
$SNGX I expect a PR or update....soon
0 · Reply
Latest News on SNGX
Soligenix reports Q1 EPS (28c) vs. (97c) last year

2026-05-08T12:43:19.000Z - 14 days ago

Soligenix reports Q1 EPS (28c) vs. (97c) last year

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026, 7:30 AM EDT - 14 days ago

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 14 days ago

Soligenix Quarterly report: Q1 2026

Soligenix Earnings release: Q1 2026

May 8, 2026, 7:00 AM EDT - 14 days ago

Soligenix Earnings release: Q1 2026

Soligenix price target lowered to $1.50 from $10 at Alliance Global

2026-05-04T11:16:01.000Z - 18 days ago

Soligenix price target lowered to $1.50 from $10 at Alliance Global

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

2026-04-28T12:08:02.000Z - 24 days ago

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Apr 28, 2026, 7:30 AM EDT - 24 days ago

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Soligenix Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 6 weeks ago

Soligenix Slides: Corporate presentation

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

2026-04-02T12:03:59.000Z - 7 weeks ago

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Apr 2, 2026, 7:30 AM EDT - 7 weeks ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Mar 31, 2026, 7:30 AM EDT - 7 weeks ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Soligenix Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 7 weeks ago

Soligenix Annual report: Q4 2025

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

2026-03-26T11:36:24.000Z - 2 months ago

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 26, 2026, 7:30 AM EDT - 2 months ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Soligenix Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 2 months ago

Soligenix Slides: Corporate presentation

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 23, 2026, 7:30 AM EDT - 2 months ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

Mar 19, 2026, 8:00 AM EDT - 2 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

Soligenix announces HyBryte clinical summary published

2026-03-19T11:36:43.000Z - 2 months ago

Soligenix announces HyBryte clinical summary published

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Mar 19, 2026, 7:30 AM EDT - 2 months ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Soligenix Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 2 months ago

Soligenix Slides: Corporate presentation

Soligenix says SGX945 granted PIM designation in UK by MHRA

2026-03-10T11:42:32.000Z - 2 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

Mar 10, 2026, 7:30 AM EDT - 2 months ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

Soligenix receives positive opinion from EMA for OOD request for dusquetide

2026-02-26T13:00:59.000Z - 3 months ago

Soligenix receives positive opinion from EMA for OOD request for dusquetide

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 26, 2026, 7:30 AM EST - 3 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Soligenix to Present at BIO Investment & Growth Summit

Feb 24, 2026, 7:30 AM EST - 3 months ago

Soligenix to Present at BIO Investment & Growth Summit

Soligenix Details Recent Progress and Upcoming Milestones

Feb 12, 2026, 7:30 AM EST - 3 months ago

Soligenix Details Recent Progress and Upcoming Milestones

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

2025-12-18T12:41:21.000Z - 5 months ago

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 5 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Soligenix announces results from Phase 2a trial of SGX302

2025-12-17T12:36:34.000Z - 5 months ago

Soligenix announces results from Phase 2a trial of SGX302

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 17, 2025, 7:30 AM EST - 5 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Dec 3, 2025, 8:30 AM EST - 6 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

2025-11-19T12:35:43.000Z - 6 months ago

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 19, 2025, 7:30 AM EST - 6 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:30 AM EST - 7 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Soligenix Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

Soligenix Quarterly report: Q3 2025

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 14, 2025, 7:30 AM EDT - 7 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

2025-10-07T11:35:32.000Z - 8 months ago

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 8 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix expands European Medical Advisory Board for CTCL

2025-09-30T11:35:29.000Z - 8 months ago

Soligenix expands European Medical Advisory Board for CTCL

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 29, 2025, 4:05 PM EDT - 8 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 8 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 23, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

2025-09-19T21:05:11.000Z - 8 months ago

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

Soligenix Registration statement: Registration Filing

Sep 19, 2025, 8:00 AM EDT - 8 months ago

Soligenix Registration statement: Registration Filing

Soligenix Slides: Corporate Presentation

Sep 19, 2025, 7:00 AM EDT - 8 months ago

Soligenix Slides: Corporate Presentation

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

2025-09-04T11:35:46.000Z - 9 months ago

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 4, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

2025-08-18T11:35:27.000Z - 9 months ago

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 18, 2025, 7:30 AM EDT - 9 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Soligenix Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Soligenix Quarterly report: Q2 2025

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 10 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Soligenix receives FDA orphan designation for dusquetide

2025-08-13T22:00:32.000Z - 10 months ago

Soligenix receives FDA orphan designation for dusquetide

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Aug 8, 2025, 8:30 AM EDT - 10 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Why Is Soligenix Stock (SNGX) Up 50% Today?

2025-08-01T01:30:00.000Z - 10 months ago

Why Is Soligenix Stock (SNGX) Up 50% Today?

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jul 1, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Jun 6, 2025, 9:37 AM EDT - 1 year ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Soligenix Quarterly report: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q1 2025

Soligenix Earnings release: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Earnings release: Q1 2025

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Soligenix Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Annual report: Q4 2024

Soligenix Earnings release: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Earnings release: Q4 2024

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Quarterly report: Q3 2024

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Quarterly report: Q3 2024

Soligenix Earnings release: Q3 2024

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Earnings release: Q3 2024

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

YoloAlfred
YoloAlfred May. 22 at 6:26 PM
$SNGX Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses - Sep 4, 2025 https://share.google/a0HcGxqysZk6Rm9a2
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 6:08 PM
$SNGX Next PR...soon.....beginning of HUMAN TRIALS....and i believe it will be fully funded through BARDA( US GOVERNMENT AGENCY) Biomedical Advanced Research and Development Authority.....You will pay $2-$4 a share after that PR
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 5:53 PM
$SNGX Im betting on it....We should have a nice LONG WEEKEND OF EBOLA DREAD sprinkled into each news cycle...this company has been working with BARDA and government. I like that Super pumpers haven't fully arrived yet...after PR ALLwill show up...im cool with it staying in the .36-.41 band
0 · Reply
rrch
rrch May. 22 at 5:46 PM
$SNGX I think an announcement is coming. They have been working on an ebola vaccine for a long time
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 3:43 PM
$SNGX added more
0 · Reply
AlertsAndNews
AlertsAndNews May. 22 at 2:26 PM
$SPY $GOVX $SIGA $LAKE $SNGX oh boy from CBS The head of the World Health Organization said Friday that the Ebola outbreak centered in the Democratic Republic of Congo is "spreading rapidly" and now poses a "very high" risk at the national level. WHO Director-General Tedros Adhanom Ghebreyesus said the United Nations health agency had raised its alert over the risks of the outbreak spreading within Congo, but that it remained lower outside the county.
1 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:49 PM
$SNGX .80-$2.20 very possible
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:47 PM
$SNGX Government support
0 · Reply
Evissamwohs
Evissamwohs May. 22 at 12:44 PM
$SNGX More shenanigans Pre Market.
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:40 PM
$SNGX I expect a PR or update....soon
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:34 PM
$SNGX 🫡😎🤠
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:34 PM
$SNGX i feel an EBOLA PR SOON
0 · Reply
YoloAlfred
YoloAlfred May. 22 at 12:33 PM
$SNGX Loading right NOW
0 · Reply
ka1954
ka1954 May. 22 at 10:23 AM
$SNGX govx stock up 400% now due to ebola threat, just on hype. SNGX is in same area has to do with EBola
0 · Reply
Evissamwohs
Evissamwohs May. 21 at 9:15 PM
$SNGX These Fing Shorts are going to suppress this into Friday to get a better price! We all know the weak Day Traders won’t hold through weekend!
0 · Reply
Evissamwohs
Evissamwohs May. 21 at 8:22 PM
$SNGX Always playing games in pre and post market trading!
0 · Reply
ka1954
ka1954 May. 21 at 8:11 PM
$SNGX just fucking go already. why so many games
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 21 at 1:03 AM
$SNGX RSI: 55.28, MACD: -0.1781 Vol: 0.38, MA20: 0.51, MA50: 0.92 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
ka1954
ka1954 May. 20 at 10:42 PM
$SNGX
0 · Reply
rrch
rrch May. 20 at 10:03 PM
$SNGX maybe a government contract. They have an ebola vaccine in development. Govt might get interested. Imo
0 · Reply
Evissamwohs
Evissamwohs May. 20 at 8:29 PM
$SNGX There is definitely some manipulation going in this!
0 · Reply
ka1954
ka1954 May. 19 at 10:09 PM
$SNGX why the fucking games? just go up already
1 · Reply